ECI-830

N/A

Report date: 2026/04/18 20:00:19
NME

Base Information

Drug NameECI-830
Drug Alias NameECI830ECI-830
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 2 inhibitors
TargetsCyclin-dependent kinase 2
Therapy Area/IndicationsSolid tumoursHR-positive breast cancer
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaCanadaUnited States +[16] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma AgChina Novartis Institutes For Biomedical Research Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursHR-positive breast cancer
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A